Filing Details

Accession Number:
0001179110-13-007589
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-02 19:04:40
Reporting Period:
2013-04-30
Filing Date:
2013-05-02
Accepted Time:
2013-05-02 19:04:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080014 Theravance Inc THRX Pharmaceutical Preparations (2834) 943265960
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1318005 W Michael Aguiar Theravance, Inc.
901 Gateway Boulevard
South San Francisco CA 94080
Sr Vp, Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-04-30 170,879 $17.91 313,365 No 4 M Direct
Common Stock Disposition 2013-04-30 160,779 $33.77 152,586 No 4 S Direct
Common Stock Disposition 2013-04-30 10,100 $34.34 142,486 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-04-30 170,879 $0.00 170,879 $17.91
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-03-06 No 4 M Direct
Footnotes
  1. DISPOSITIONS MADE PURSUANT TO A PLAN INTENDED TO COMPLY WITH RULE 10b5-1(c).
  2. This transaction was executed in multiple trades at prices ranging from $33.31 to $34.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $34.31 to $34.36. The price reported above reflects the weighted average sale price.
  4. Immediately exercisable.